Please provide your email address to receive an email when new articles are posted on . Aaron T. Gerds, MD, MS, spoke with Healio about the REVEAL study, results of which were presented at this year’s ...

Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.

Credit: Thinkstock. The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

NEWARK, Calif., Dec. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating ...

(BPT) – Polycythemia vera (PV) is a rare, chronic cancer that leads to overproduction of red blood cells, increasing the “stickiness” of blood. People with PV experience a range of symptoms, some of ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks. Patients switching from placebo to rusfertide achieved rapid and ...

Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism. Men on testosterone therapy who ...

Over 10% of transgender men (females transitioning to male) who take testosterone develop high hematocrit levels that could put them at greater risk for a thrombotic event, and the largest increase in ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...